Literature DB >> 17631311

Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody.

Christopher N Scanlan1, Gayle E Ritchie, Kavitha Baruah, Max Crispin, David J Harvey, Bernhard B Singer, Lothar Lucka, Mark R Wormald, Paul Wentworth, Nicole Zitzmann, Pauline M Rudd, Dennis R Burton, Raymond A Dwek.   

Abstract

The HIV envelope has evolved a dense array of immunologically "self" carbohydrates that efficiently protect the virus from antibody recognition. Nonetheless, one broadly neutralising antibody, IgG1 2G12, has been shown to recognise a cluster of oligomannose glycans on the HIV-1 surface antigen gp120. Thus the self carbohydrates of HIV are now regarded as potential targets for viral neutralisation and vaccine design. Here, we show that chemical inhibition of mammalian glycoprotein synthesis, with the plant alkaloid kifunensine, creates multiple HIV (2G12) epitopes on the surface of previously non-antigenic self proteins and cells, including HIV gp120. This formally demonstrates the structural basis for self/non-self discrimination between viral and host glycans, by a neutralising antibody. Moreover, this study provides an alternative protein engineering approach to the design of a carbohydrate vaccine for HIV-1 by chemical synthesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631311     DOI: 10.1016/j.jmb.2007.06.027

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  44 in total

Review 1.  Emerging technologies for making glycan-defined glycoproteins.

Authors:  Lai-Xi Wang; Joseph V Lomino
Journal:  ACS Chem Biol       Date:  2011-12-14       Impact factor: 5.100

2.  Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.

Authors:  Katie J Doores; Zara Fulton; Michael Huber; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

3.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Authors:  Katie J Doores; Camille Bonomelli; David J Harvey; Snezana Vasiljevic; Raymond A Dwek; Dennis R Burton; Max Crispin; Christopher N Scanlan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

4.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

5.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

6.  Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.

Authors:  Guozhang Zou; Hirofumi Ochiai; Wei Huang; Qiang Yang; Cishan Li; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2011-11-01       Impact factor: 15.419

7.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

8.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 9.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

10.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.